The role of serotonin inhibition within the treatment of carcinoid syndrome
Open Access
- 20 April 2023
- journal article
- review article
- Published by Bioscientifica in Endocrine Oncology
- Vol. 3 (1) , e220077
Abstract
Carcinoid syndrome is the most frequent hormonal complication associated with neuroendocrine neoplasms. It was first reported in 1954, and the classical symptoms are diarrhoea, flushing and abdominal pain. It is caused by the secretion of several vasoactive substances, the most prominent being serotonin, which play a pathophysiological role in the clinical symptoms which characterise carcinoid syndrome. Therefore, the focus of carcinoid syndrome treatment is to reduce serotonin production and hence improve the patient’s quality of life. There are a variety of management options for carcinoid syndrome including medical, surgical and loco-regional interventional radiological procedures. The most widely used are somatostatin analogues with three clinically approved drugs: lanreotide and octreotide (first-generation) and pasireotide (second-generation). Both everolimus and interferon used in combination with octreotide have shown significant reduction in urinary 5-hydroxyindoleacetic acid compared to octreotide alone. Telotristat ethyl has been increasingly utilised for patients with symptoms despite taking somatostatin analogues. It has also been shown to have a significant improvement in bowel movement frequency which was associated with a significant improvement in quality of life. Peptide receptor radionuclide therapy has proven symptomatic improvement in patients with uncontrolled symptoms. Chemotherapy is primarily reserved for patients with high proliferation tumours, with limited research on the efficacy in reducing symptoms. Surgical resection remains the optimal treatment due to being the only one that can achieve a cure. Liver-directed therapies are considered in patients where curative resection is not possible. There are therefore numerous different therapies. This paper describes the pathophysiology and therapy of carcinoid syndrome.Keywords
This publication has 59 references indexed in Scilit:
- The 5‐HT2Breceptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironmentCancer, 2010
- Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictorsHPB, 2007
- Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative studyHealth and Quality of Life Outcomes, 2007
- The Diagnosis and Medical Management of Advanced Neuroendocrine TumorsEndocrine Reviews, 2004
- Surgery for midgut carcinoid.Endocrine-Related Cancer, 2003
- Aggressive surgery for metastatic liver neuroendocrine tumorsSurgery, 2003
- Ki67, E-CADHERIN, AND p53 AS PROGNOSTIC INDICATORS OF LONG-TERM OUTCOME AFTER LIVER TRANSPLANTATION FOR METASTATIC NEUROENDOCRINE TUMORSTransplantation, 2002
- Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferonActa Oncologica, 1993
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986
- Differences in the degradation of hypothalamic releasing factors by rat and human serumLife Sciences, 1976